Following people in China with antiphospholipid syndrome antibodies over time

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people in China whose blood tests show antiphospholipid antibodies (aPL) that stay positive over time. It is an observational study that follows these people.

Sex

All sexes can join.

Disease stage

People with lasting positive antiphospholipid antibodies, with or without signs of antiphospholipid syndrome (APS).

Biomarker or test result

One or more antiphospholipid antibodies (aPL), tested as set by the 2006 Sapporo APS classification criteria. They must be positive on 2 or more occasions at least 12 weeks apart.

Main reasons for not taking part

• People who refuse to take part cannot join.
• People who cannot be followed over time cannot join.

The registry criteria, word for word

What the trial wants to find out

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and pregnancy morbidity in patients with persistently positive antiphospholipid antibodies (aPLs). However, large-scale research on general population with persistent aPLs has been lacking. This project proposes to establish the first multicenter cohort of patients with persistently positive aPLs in China and conduct a comprehensive clinical phenotyping study. Based on traditional phenotypes of thrombotic and pregnancy events, the focus will be on extra-standard clinical phenotypes and prospective assessment of event risk and prognosis in aPL-positive population. A prospective analysis of extra-standard antibodies will also be conducted to recommend detection criteria for extra-standard antibody application in China and to assess their clinical significance.